Lataa...

Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials

BACKGROUND: Cystic fibrosis (CF) pulmonary exacerbations can be serious respiratory events and reduction in exacerbation rate or risk are important efficacy endpoints for CF therapeutic trials. Variability in exacerbation diagnoses and treatment have led drug developers to employ “objective” exacerb...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Cyst Fibros
Päätekijät: VanDevanter, Donald R., Hamblett, Nicole Mayer, Simon, Noah, McIntosh, Joseph, Konstan, Michael W.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: European Cystic Fibrosis Society. Published by Elsevier B.V. 2021
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362840/
https://ncbi.nlm.nih.gov/pubmed/32682670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcf.2020.07.008
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!